Technical Analysis for AGEN - Agenus Inc.

Grade Last Price % Change Price Change
grade D 3.94 2.34% 0.09
AGEN closed up 2.34 percent on Friday, January 17, 2020, on 1.34 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical AGEN trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Gapped Up Strength 0.00%
Up 3 Days in a Row Strength 0.00%
20 DMA Resistance Bearish 2.34%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.34%
Pocket Pivot Bullish Swing Setup 5.91%
Lower Bollinger Band Walk Weakness 5.91%
Oversold Stochastic Weakness 5.91%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer's disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company's products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Medicine Biotechnology Health Cancer Clinical Medicine Infectious Diseases Cancers Alzheimer's Disease Non Small Cell Lung Cancer Vaccination Melanoma Vaccine Metastatic Melanoma Glioma Renal Cell Carcinoma Malaria Cancer Vaccines Oncophage Agenus Experimental Cancer Treatments Genital Herpes Herpes Simplex Research Shingles

Is AGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.57
52 Week Low 2.135
Average Volume 1,293,208
200-Day Moving Average 3.02
50-Day Moving Average 3.91
20-Day Moving Average 3.87
10-Day Moving Average 3.69
Average True Range 0.21
ADX 18.76
+DI 29.62
-DI 22.69
Chandelier Exit (Long, 3 ATRs ) 3.70
Chandelier Exit (Short, 3 ATRs ) 3.93
Upper Bollinger Band 4.30
Lower Bollinger Band 3.43
Percent B (%b) 0.58
BandWidth 22.60
MACD Line -0.04
MACD Signal Line -0.03
MACD Histogram -0.0063
Fundamentals Value
Market Cap 392.86 Million
Num Shares 99.7 Million
EPS -1.26
Price-to-Earnings (P/E) Ratio -3.13
Price-to-Sales 8.62
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.23
Resistance 3 (R3) 4.24 4.16 4.18
Resistance 2 (R2) 4.16 4.08 4.15 4.17
Resistance 1 (R1) 4.05 4.04 4.10 4.04 4.15
Pivot Point 3.96 3.96 3.99 3.96 3.96
Support 1 (S1) 3.85 3.89 3.91 3.84 3.73
Support 2 (S2) 3.77 3.84 3.76 3.71
Support 3 (S3) 3.66 3.77 3.70
Support 4 (S4) 3.65